Miguel J M, Nunes A C, Gonçalves F R, Pêgo G M
Cadeira de Medicina Preventiva, Faculdade de Medicina de Lisboa.
Rev Port Cardiol. 1991 Dec;10(12):931-9.
A short-term trial of isradipine was conducted in order to assess its effectiveness and tolerability in the treatment of mild to moderate HT. The study took place in general practice on 2702 patients, aged 18 to 70, with diastolic BP (dBP) from 95 to 114 mmHg. It included a pretreatment phase of up to four weeks out of antihypertensive drugs and on placebo and a twelve week treatment phase on isradipine 2.5 mg or 5.0 mg/day. After treatment with isradipine sBP fell from 168.0 to 148.1 and dBP from 102.7 to 86.7 mmHg. The majority of patients (89.6%) had a fall in dBP over 10 mmHg; 86.2% had normal dBP (= less than 90 mmHg) in the end. Adverse effects were referred by 2.8% of the patients. Satisfaction with the drug reached 90% among patients and physicians. Thus, isradipine proved effective and very well tolerated and may deserve a place as first line treatment for hypertension.
为评估伊拉地平治疗轻至中度高血压（HT）的有效性和耐受性，开展了一项短期试验。该研究在普通医疗环境中对2702例年龄在18至70岁、舒张压（dBP）为95至114 mmHg的患者进行。研究包括长达四周的停用抗高血压药物并服用安慰剂的预处理阶段，以及为期十二周的服用2.5毫克或5.0毫克/天伊拉地平的治疗阶段。服用伊拉地平治疗后，收缩压（sBP）从168.0降至148.1，舒张压从102.7降至86.7 mmHg。大多数患者（89.6%）的舒张压下降超过10 mmHg；最终86.2%的患者舒张压正常（即低于90 mmHg）。2.8%的患者报告有不良反应。患者和医生对该药物的满意度达到90%。因此，伊拉地平被证明是有效的，耐受性非常好，可能值得作为高血压的一线治疗药物。
